Compare KGS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KGS | CELC |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | 2023 | 2017 |
| Metric | KGS | CELC |
|---|---|---|
| Price | $75.73 | $123.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $57.17 | ★ $112.56 |
| AVG Volume (30 Days) | ★ 1.3M | 939.9K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | ★ 58.93 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $1,308,100,000.00 | N/A |
| Revenue This Year | $12.30 | N/A |
| Revenue Next Year | $7.96 | $720.19 |
| P/E Ratio | $375.50 | ★ N/A |
| Revenue Growth | ★ 12.83 | N/A |
| 52 Week Low | $30.06 | $10.26 |
| 52 Week High | $76.68 | $151.02 |
| Indicator | KGS | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 79.56 | 49.39 |
| Support Level | $33.33 | $100.58 |
| Resistance Level | N/A | $151.02 |
| Average True Range (ATR) | 2.40 | 8.22 |
| MACD | 0.57 | -0.89 |
| Stochastic Oscillator | 92.24 | 38.88 |
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.